Randal D. Chase Purchases 10,000 Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) Stock

GeoVax Labs, Inc. (NASDAQ:GOVXGet Rating) Director Randal D. Chase purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 21st. The stock was purchased at an average price of $1.10 per share, with a total value of $11,000.00. Following the completion of the purchase, the director now directly owns 36,613 shares of the company’s stock, valued at approximately $40,274.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

GeoVax Labs Price Performance

NASDAQ:GOVX traded up $0.00 during mid-day trading on Friday, reaching $1.00. The stock had a trading volume of 13,349 shares, compared to its average volume of 6,380,700. The stock’s 50 day simple moving average is $1.72 and its two-hundred day simple moving average is $1.37. GeoVax Labs, Inc. has a 1-year low of $0.55 and a 1-year high of $5.61. The company has a market capitalization of $24.74 million, a price-to-earnings ratio of -0.32 and a beta of 3.29.

Hedge Funds Weigh In On GeoVax Labs

A number of large investors have recently bought and sold shares of the business. Renaissance Technologies LLC bought a new position in GeoVax Labs in the second quarter worth about $333,000. Virtu Financial LLC lifted its holdings in GeoVax Labs by 39.1% in the second quarter. Virtu Financial LLC now owns 69,093 shares of the company’s stock worth $57,000 after acquiring an additional 19,409 shares during the last quarter. Finally, Millennium Management LLC bought a new position in GeoVax Labs in the second quarter worth about $27,000. Institutional investors own 25.63% of the company’s stock.

GeoVax Labs Company Profile

(Get Rating)

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.

Recommended Stories

Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.